Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Company Overview - Nyxoah is a medical technology company focused on developing and commercializing innovative solutions for treating Obstructive Sleep Apnea (OSA) [3] - The company's lead product is the Genio system, which is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for OSA [3] Recent Developments - Nyxoah will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference from March 16 to 19, 2026 [1] - CEO Olivier Taelman will present on March 16, 2026, at 8:40 am ET, with a webcast available on the company's Investor Relations website [2] - The company will also hold one-on-one meetings with institutional investors during the conference [2] Product Milestones - The Genio system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [4] - Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021 [4] - The company received CE mark approval for expanding therapeutic indications to Complete Concentric Collapse (CCC) patients after positive outcomes from the BETTER SLEEP study [4] - The FDA approved the Genio system for a subset of adult patients with moderate to severe OSA in August 2025 [4]